Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 4 of 4

Full-Text Articles in Medicine and Health Sciences

Change In Brain Volume And Cortical Thickness After Behavioral And Surgical Weight Loss Intervention, Cara Bohon, Allan Geliebter Dec 2018

Change In Brain Volume And Cortical Thickness After Behavioral And Surgical Weight Loss Intervention, Cara Bohon, Allan Geliebter

Lander College of Arts and Sciences Publications and Research

Obesity is associated with reduced cortical thickness and brain volume, which may be related to poor nutrition. Given that brain atrophy in anorexia nervosa recovers with nutritional improvements and weight gain, it is worth examining how brain structure changes at the other end of the weight spectrum with weight loss. Thus, this study aimed to examine change in cortical thickness and brain volume in 47 patients with severe obesity who participated in no treatment, behavioral weight loss, or bariatric surgery. T1-weighted MRI scans were conducted pre-treatment and approximately four months later. Measures of cortical thickness, gray matter volume, and white …


A Randomized Controlled Dosing Study Of Iyengar Yoga And Coherent Breathing For The Treatment Of Major Depressive Disorder: Impact On Suicidal Ideation And Safety Findings, Maren Nyer, Patricia Gerbarg, Marisa M. Silveri, Jennifer Johnston, Tammy M. Scott, Maya Nauphal, Liz Owen, Greylin H. Nielsen, David Mischoulon, Richard P. Brown, Maurizio Fava, Chris C. Streeter Apr 2018

A Randomized Controlled Dosing Study Of Iyengar Yoga And Coherent Breathing For The Treatment Of Major Depressive Disorder: Impact On Suicidal Ideation And Safety Findings, Maren Nyer, Patricia Gerbarg, Marisa M. Silveri, Jennifer Johnston, Tammy M. Scott, Maya Nauphal, Liz Owen, Greylin H. Nielsen, David Mischoulon, Richard P. Brown, Maurizio Fava, Chris C. Streeter

NYMC Faculty Publications

BACKGROUND: Yoga interventions offer promise for the treatment of major depressive disorder (MDD), yet their safety and potential impact on suicidal ideation (SI) have not been well documented. This study evaluated the safety of a randomized controlled dose-finding trial of Iyengar yoga plus coherent breathing for individuals with MDD, as well as the potential effects of the intervention on SI without intent. METHODS: Participants with Beck Depression Inventory-II (BDI-II) scores >/=14 and a diagnosis of MDD (using DSM-IV criteria) were randomized to either a low dose group (LDG) or high dose group (HDG) and received a 12-week manualized intervention. The …


Nyx-2925 Is A Novel Nmda Receptor-Specific Spirocyclic-Beta-Lactam That Modulates Synaptic Plasticity Processes Associated With Learning And Memory, M. Amin Khan, David R. Houck, Amanda L. Gross, Xiao-Lei Zhang, Cassia Cearley, Patric K. Stanton, Joseph R. Moskal Mar 2018

Nyx-2925 Is A Novel Nmda Receptor-Specific Spirocyclic-Beta-Lactam That Modulates Synaptic Plasticity Processes Associated With Learning And Memory, M. Amin Khan, David R. Houck, Amanda L. Gross, Xiao-Lei Zhang, Cassia Cearley, Patric K. Stanton, Joseph R. Moskal

NYMC Faculty Publications

Background: N-methyl-D-aspartate receptors are one member of a family of ionotropic glutamate receptors that play a pivotal role in synaptic plasticity processes associated with learning and have become attractive therapeutic targets for diseases such as depression, anxiety, schizophrenia, and neuropathic pain. NYX-2925 ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide) is one member of a spiro-beta-lactam-based chemical platform that mimics some of the dipyrrolidine structural features of rapastinel (formerly GLYX-13: threonine-proline-proline-threonine) and is distinct from known N-methyl-D-aspartate receptor agonists or antagonists such as D-cycloserine, ketamine, MK-801, kynurenic acid, or ifenprodil. Methods: The in vitro and in vivo pharmacological properties of NYX-2925 were examined. Results: NYX-2925 has …


Relationships Between Clinical Scales And Binge Eating Days In Adults With Moderate To Severe Binge Eating Disorder In Two Phase Iii Studies, Leslie L. Citrome, Judith C. Kando, Caleb Bliss Feb 2018

Relationships Between Clinical Scales And Binge Eating Days In Adults With Moderate To Severe Binge Eating Disorder In Two Phase Iii Studies, Leslie L. Citrome, Judith C. Kando, Caleb Bliss

NYMC Faculty Publications

OBJECTIVES:

In two Phase III studies, lisdexamfetamine dimesylate (LDX) reduced binge eating (BE) days/week in adults with moderate to severe binge eating disorder (BED) and was associated with improvement based on the Clinical Global Impressions-Improvement (CGI-I) scale. In this study, post hoc analyses examined the relationships between clinical observations and clinical rating scales in individuals with BED.

CLINICAL TRIAL REGISTRATION:

NCT01718483 (ClinicalTrials.gov/ct2/show/NCT01718483); NCT01718509(ClinicalTrials.gov/ct2/show/NCT01718509).

METHODS:

Two 12-week, double-blind, placebo-controlled studies randomized (1:1) adults meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, BED criteria and with protocol-defined moderate to severe BED (study …